Showing 4451-4460 of 5771 results for "".
- Avellino Introduces Multiplex Respiratory Panel for Simultaneous Detection of COVID-19 and Influenzahttps://modernod.com/news/avellino-introduces-multiplex-respiratory-panel-for-simultaneous-detection-of-covid-19-and-influenza/2478505/Avellino announced that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the FDA’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing CLIA guidelines. The AvellinoCoV
- Early Phase 3 Data Show Pfizer, BioNTech’s COVID-19 Vaccine Over 90% Effectivehttps://modernod.com/news/early-phase-3-data-show-pfizer-biontechs-covid-19-vaccine-over-90-effective/2478507/Results from the first interim analysis of a phase 3 study of Pfizer and BioNTech’s BNT162b2 showed that the experimental mRNA-based vaccine candidate was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced M
- Oxurion NV Confirms New Patents for THR-687 Issued by European and US Patent Officeshttps://modernod.com/news/oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices/2478504/Oxurion NV announced a strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME. The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-o
- Staar Surgical Begins Commercialization of EVO Viva Presbyopia Correcting Lenshttps://modernod.com/news/staar-surgical-begins-commercialization-of-evo-viva-presbyopia-correcting-lens/2478495/Staar Surgical announced the initial commercialization of its EVO Viva presbyopia correcting lens including the first patient implant. “The first patient received his EVO Viva lenses on October 23 in Belgium from Dr. Erik Mertens, and we are delighted to hear from Dr. Mertens that the pati
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-
- Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for Lytenava for Retinal Diseaseshttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-of-open-label-safety-study-for-lytenava-for-retinal-diseases/2478490/Outlook Therapeutics announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/Lytenava (NORSE THREE). Patient enrollment for the study was completed in less than 1 month, ahead of the planned 4-month enrollment schedule.
- Aurinia Pharmaceuticals’ Dry Eye Drug Candidate Does Not Meet Primary Endpointhttps://modernod.com/news/aurinia-announces-outcome-of-audrey-clinical-trial-in-dry-eye-syndrome/2478487/Aurinia Pharmaceuticals announced topline data from the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). The trial did not achieve statistical significance on its primary endpoint of a 10 mm or greater improvem
- PolyActiva Appoints Tracy Valorie to its Board of Directorshttps://modernod.com/news/polyactiva-appoints-tracy-valorie-to-its-board-of-directors/2478481/PolyActiva announced the appointment of experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors. Ms. Valorie is recognized in the industry for her success in building and leading high performing teams a
- Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseaseshttps://modernod.com/news/ocumension-therapeutics-strengthens-pipeline-for-posterior-segment-eye-diseases/2478482/Ocumension Therapeutics announced that the company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology, a wholly-owned subsidiary of Luye Pharma Group, to jointly develop OT-702 (LY09004), a biosimilar to Eylea (aflibercept). Ocumension has
- CMS: Medicare to Cover COVID-19 Vaccine At No Cost to Beneficiarieshttps://modernod.com/news/cms-medicare-to-cover-covid-19-vaccine-at-no-cost-to-beneficiaries/2478476/The Trump administration announced it will cover a vaccine for COVID-19 at no cost to Medicare beneficiaries when it gets approved, according to a FierceHealthcare report. The Centers for Medicare & Medicaid Services released an interim rule on Wednesday that aims to remove regulatory